Israeli company KAHR Medical, which develops treatments for cancer and inflammatory disease, specifically lymphoma, has announced that it has raised $2.35 million from its shareholders at a company value of $13.2 million.
The company intends to use the proceeds in order to begin human trials in early 2014.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments